Cramer looks at Illumina, Archer Aviation, NANO Nuclear Energy, Steris, Sixth Street Specialty Lending, Lam Research and ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

Canaccord lowered the firm’s price target on Illumina (ILMN) to $115 from $135 and keeps a Hold rating on the shares. The firm’s target ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Illumina completed the deal just under a year ... parties to transactions that are not notifiable to the EC or any Member State can no longer rest assured that the EC will not review their ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

As U.S. antitrust counsel to global companies, it is increasingly important to track major developments in the international ...

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...